ライフサイエンスコーパス: vehicle control

1 eoxyguanosine by 61% (P < 0.01 compared with vehicle control).

2 injected with doxorubicin, 3 mg/kg/week, or vehicle (control).

3 itor to reduce visceral hypersensitivity, or vehicle (control).

4 weeks to induce features of Parkinsonism, or vehicle (control).

5 liance; P < 0.05 compared with untreated and vehicle controls).

6 stinal inflammation compared with mice given vehicle (controls).

7 rty-eight mice received nebulized LPS or the vehicle (controls).

8 ), scopolamine (5, 25 and 100 mug kg(-1)) or vehicle (controls).

9 about 10 times lower with 10 muM Lat-B than vehicle control.

10 nts compared with those in the COH rats with vehicle control.

11 pon treatment with ganciclovir, but not with vehicle control.

12 antly above either factor alone as well as a vehicle control.

13 a cells treated with genistein compared with vehicle control.

14 Cells were exposed to teduglutide or vehicle control.

15 direct thrombin inhibitor and compared with vehicle control.

16 flammatory foci per muscle field relative to vehicle control.

17 duction in tumour growth (p = 0.005), 56% of vehicle control.

18 or growth was inhibited by 75% compared with vehicle control.

19 EU, 0.08 EU, and 0.02 EU of endotoxin or the vehicle control.

20 he conjunctiva (P </= 0.05) as compared with vehicle control.

21 aly detection, medical diagnosis and robotic vehicle control.

22 detected in DNFB-treated ears compared with vehicle control.

23 the immunoproteasome inhibitor ONX 0914, or vehicle control.

24 male rats underwent oral gavage with THC or vehicle control.

25 ture incubated with each FFA, but not with a vehicle control.

26 Recipient mice were treated with TAK-779 or vehicle control.

27 57-B mice received an antipsychotic agent or vehicle control.

28 L-2 production compared with BMDC exposed to vehicle control.

29 ed with Fancc(-/-) donor cells cultured with vehicle control.

30 ions of the LXR agonists T1317 and GW3965 or vehicle control.

31 1, 3, or 5 nMol/kg of CCK-33, CCK-8, or the vehicle control.

32 ed intravitreal injections of azurocidin and vehicle control.

33 induction of caspase-3 and Bax, compared to vehicle control.

34 groups of 10 ng/d CNTF, 1 ng/d CNTF, and PBS vehicle control.

35 N-S-phenyl-glycine-t-butyl ester (DAPT), or vehicle control.

36 rease caspase-3 activation compared with the vehicle control.

37 ze of adhesions (P < 0.05) compared with the vehicle control.

38 increased adhesion formation compared to the vehicle control.

39 period with melatonin (0.6 mg) or 2% ethanol vehicle control.

40 ient ACI rats were pretreated with M40401 or vehicle control.

41 dine (TFT) and balanced salt solution as the vehicle control.

42 l cell loss relative to animals administered vehicle control.

43 in power output of muscles when compared to vehicle control.

44 ty by 21% and 30%, respectively, compared to vehicle control.

45 lostazol (phosphodiesterase 3 inhibitor), or vehicle control.

46 56% of mice that received high-dose RT with vehicle control.

47 testinal tissue of infected mice compared to vehicle control.

48 cted mice treated with S1PR agonist AAL-R or vehicle control.

49 mice in the corticosterone group relative to vehicle control.

50 d with penicillin-streptomycin (PenStrep) or vehicle control.

51 r 4T1 tumors compared to 67NR tumors and the vehicle control.

52 urvival in I-BET151 treated mice compared to vehicle control.

53 the retinae of Rho(P23H/+) mice compared to vehicle control.

54 generation, as compared to mice treated with vehicle control.

55 esion formation compared to treatment with a vehicle control.

56 d from host mice after treatment with JQ1 or vehicle control.

57 p-aminobenzoate, and escin as compared with vehicle control.

58 at twice rheobase compared with neurons from vehicle controls.

59 effect on baseline ED performance in chronic vehicle controls.

60 lly reduce tumor volumes over paclitaxel and vehicle controls.

61 ition that normally promotes cue strategy in vehicle controls.

62 629 increased and 423 decreased) compared to vehicle controls.

63 c parameters or cellular localization in the vehicle controls.

64 increase in ppET-1 mRNA content compared to vehicle controls.

65 erage net displacement by >/=80% relative to vehicle controls.

66 wer in Cl-amidine-treated mice compared with vehicle controls.

67 severe histological inflammation compared to vehicle controls.

68 ive and citrullinated epitopes compared with vehicle controls.

69 ic raft cultures compared with the level for vehicle controls.

70 n highly sensitive M229 cells, compared with vehicle controls.

71 rct (% contralateral hemisphere) compared to vehicle controls.

72 at reducing freezing behavior as compared to vehicle controls.

73 fewer conditioned responses than unstressed vehicle controls.

74 atment in all treatment groups compared with vehicle controls.

75 etreated with control adenovirus (AdNull) or vehicle controls.

76 sed in rats treated with SC58125 compared to vehicle controls.

77 /SS cell lines and patients' PBL compared to vehicle controls.

78 of the I/M ratio and %LN when compared with vehicle controls.

79 at 24 hr, but not 1 week, compared with the vehicle controls.

80 ntries in response to the tone compared with vehicle controls.

81 the medial basal hypothalamus compared with vehicle controls.

82 ra of the aged GDNF recipients compared with vehicle controls.

83 23-fold increase in apoptosis compared with vehicle controls.

84 3 hr to 3 d after injury, compared with the vehicle controls.

85 nal microvessel density by 80% compared with vehicle controls.

86 peak lactate after reperfusion compared with vehicle controls.

87 reater collagen deposition, when compared to vehicle controls.

88 levels within the aortic wall as compared to vehicle controls.

89 d with AAV9-MIS, recombinant MIS protein, or vehicle controls.

90 inhibitor showed higher platelet counts than vehicle controls.

91 antly reduced cell death at 48 h compared to vehicle control (0.1% DMSO) when administered 0, 1, 6, a

92 ere perfused with medium containing either a vehicle control (0.1% ethanol [ETH]) or dexamethasone (D

93 -week-old APC(min/+) mice were p.o. fed with vehicle control (0.5% carboxymethyl cellulose and 0.025%

94 d daily treatment by oral gavage with either vehicle control (0.5% methylcellulose) or 10 or 30 mg/kg

95 daily for 12 days (oral gavage) with either vehicle (control, 0.5% w/v hydroxypropyl-methylcellulose

96 (4.2+/-2.2%) as compared to their respective vehicle controls (2.5+/-1.4% and 4.6+/-1%).

97 bits were randomly assigned to 3 groups: (1) vehicle control, (2) SAHA pretreatment (1 day before and

98 our treatment groups (n = 12 per group): (1) vehicle control; (2) 5 mg/kg/day LANZO; (3) 5 mg/kg/day

99 ading with VEGF-A injection when compared to vehicle control (26+/-2 vs. 3+/-1 mum/s, P<0.05).

100 Mice were exposed to Room Air, vehicle control (50%VG/%50PG), Black Licorice, Kola, Ban

101 andomly assigned one of four treatments: (1) vehicle control (90% propylene glycol + 10% lactated Rin

102 nonhuman nucleic acids and their respective vehicle controls, a denatured cohesive ophthalmic viscos

103 s pancreatic tumors received oral FG-4592 or vehicle control +/- ablative RT to a cumulative 75 Gy ad

104 Compared with vehicle controls, administration of RvE1 resulted in sig

105 ctional deficits compared with corresponding vehicle-controls, after 45 and 60 min of ischemia.

106 and PI3 (by 65%) versus scrambled L-SNA and vehicle controls (all P < 0.001).

107 e bengal staining compared with NGF, DHA, or vehicle control alone.

108 No reactions to the vehicle control and 3 mg/kg BADGE were observed.

109 gens reduced cell numbers below those of the vehicle control and also activated caspases.

110 Eight sheep received on 2 separate days a vehicle control and incremental intravenous boluses of a

111 vely, relative to the difference between the vehicle control and lean hGCGR mice.

112 aquaphilic was vastly superior to a negative vehicle control and was comparable in efficacy to a posi

113 D/beige mice receiving systemic rapamycin or vehicle control and were analyzed 21 d later.

114 sleep time, compared with both within-animal vehicle controls and between-animal time-controls.

115 21(waf1) were all decreased when compared to vehicle controls and FVB/N mice.

116 antly greater than the Pre and corresponding vehicle controls and non-responsive neurons.

117 d-PSC-transplanted testes compared to intact vehicle controls and the luteinising hormone/testosteron

118 ells (1.40+/-0.02-fold, P<0.01 compared with vehicle control) and an EGFR/HER2 inhibitor blocked this

119 ion (85 and 70%, respectively, compared with vehicle control) and reduced foam cell formation (approx

120 mice were concomitantly treated with DEX (or vehicle control) and Scl-AbI antibody (or isotype-matche

121 erformed on eyes exposed to albumin, protein vehicle control, and the OVDs at these time points.

122 ectrical stimulation in PGi increased ECG in vehicle control animals, but decreased it in estradiol-t

123 Compared with vehicle control animals, peanut recall responses in sple

124 arcinoma by 220 days, compared to 50% in the vehicle control animals.

125 All vehicle-control animals died, whereas 83% of animals rec

126 ion, liver function, and coagulopathy versus vehicle-control animals.

127 uced to 64-fold below the mean viral load in vehicle control at day 24.

128 ation and protein concentration) compared to vehicle controls at the two lower doses, but elevated mo

129 % [Restasis, Allergan Inc., Irvine, CA]), or vehicle control BID for 8 weeks.

130 nctival injections of exogenous IFN-gamma or vehicle control (BSA) at days 0, +2, and +4 after DS.

131 in streptozotocin-induced DM or age-matched vehicle controls by whole-cell patch clamp at 5- or 10-w

132 s postponed in dextrose-infused mice (versus vehicle control) by an interval of time comparable to th

133 ed cells could be clearly distinguished from vehicle control cells (0 muM AMIO) and HepaRG cells from

134 mice had fewer evoked seizures compared with vehicle controls, coinciding with greater preservation o

135 Dams received cocaine (COC) or vehicle (control, CON) intravenously from gestation day

136 thylprednisolone, 0.05% cyclosporin A, and a vehicle control containing carboxymethylcellulose sodium

137 topical fluorouracil cream, 5% (n = 468), or vehicle control cream (n = 464) to the face and ears twi

138 o apply topical fluorouracil, 5%, cream or a vehicle control cream to the face and ears twice daily f

139 thrombin but not with injection of PBS as a vehicle control, demonstrating the first aptamer-based a

140 Using a cross-over, double-blind, vehicle-controlled design, 22 heroin-dependent and heroi

141 istically significant difference compared to vehicle control despite tumor volume being reduced to le

142 e treated with phosphate buffered saline (as vehicle control), dexamethasone (as positive control), o

143 ing the first 3 h, mTBI alone, compared with vehicle control, did not alter total distance travelled.

144 Nine vehicle control earthworms were sacrificed at days 6 and

145 793 vs 39,095 um(2), *p < 0.05)) compared to vehicle control, enhanced new epithelial cell division,

146 Term DC cultures were incubated with vehicle (control), estradiol (E2) with or without medrox

147 monary reflex, when compared to time-matched vehicle control experiments, intracisternal application

148 ents to topical 0.1% tretinoin or a matching vehicle control for 1.5-5.5 years.

149 arctigenin at 50 mg/kg body weight daily or vehicle control for 6 weeks.

150 with a reference chemical (phenobarbital) or vehicle control for 7 days.

151 e application of 0.5% ivermectin lotion with vehicle control for the elimination of infestations with

152 tive COX-2 inhibitor parecoxib (25 mg/kg) or vehicle (control) for 7 and 28 days.

153 r =90% purified EPA, DHA, oleic acid (OA) or vehicle control, for 4.5 d.

154 e administered broad-spectrum antibiotics or vehicle-control from the age of 6 to 12 weeks.

155 Relative to vehicle controls, GP attenuated several effects of HFD f

156 ly, 0.5% once daily, or 0.15% once daily) or vehicle (control group) twice daily on lesions constitut

157 , 0.5 mg estradiol benzoate (E2; n = 10), or vehicle (control group, CNT; n = 10).

158 showed decreased activity compared with the vehicle control group in response to a low-dose cocaine

159 Relative to the vehicle control group, mice receiving corticosterone had

160 length and branching number relative to the vehicle control group.

161 xpression was significantly less than in the vehicle control group.

162 r nuclei remained, but in the retinas of the vehicle-control group only 38.0% of these nuclei remaine

163 ol (P<0.001 for each treatment group vs. the vehicle-control group).

164 h of the paromomycin groups and three in the vehicle-control group.

165 equent in the paromomycin groups than in the vehicle-control group.

166 compared with results in the single-drug and vehicle control groups.

167 sulted in decreased tumor volume compared to vehicle control; however, while the effect was in the sa

168 ecreased in (+)-JQ1 treated mice compared to vehicle control; however, while the effect was in the sa

169 3019 (HRHF-Rest/FG-3019) or a human IgG as a vehicle control (HRHF-Rest/IgG).

170 nfiltrated with 0.4 mL ETC-216 (14 mg/mL) or vehicle control immediately before deployment of GFX ste

171 he NHE-1 inhibitor zoniporide (3 mg.kg-1) or vehicle control immediately before starting extracorpore

172 in a lower median disease burden compared to vehicle control in all tissues analyzed, similar to the

173 cation of ivermectin was more effective than vehicle control in eliminating head-louse infestations a

174 performance interact to influence simulated vehicle control in glaucoma drivers.

175 ed activated caspase3 staining compared with vehicle control in HCC1954 tumors.

176 s (ERB-041 or WAY-202196) were compared with vehicle control in the murine cecal ligation and punctur

177 improved acquisition of memory compared with vehicle controls in a reference-memory Morris water-maze

178 with the Ox1r antagonist did not differ from vehicle controls in locomotor activity following acute-

179 The high rate of comparisons with vehicle controls in randomized controlled trials that as

180 rall survival vs. mice treated with dEpoB or vehicle control, indicating that Flu may be a promising

181 Relative to vehicle controls, infusion of U0126 impaired training-in

182 cted with TNF (5 mug/mouse for 3-6 hours) or vehicle (control); intestines were collected and analyze

183 crease in capillary density by comparison to vehicle control, intramuscular vs. oral administration o

184 This phase 2a, single-center, vehicle-controlled, intrapatient study was designed to f

185 hey received either a dorsal CA3 lesion or a vehicle control lesion.

186 led cells was not significantly changed from vehicle control levels following either acute (1, 3, 10,

187 ising hormone/testosterone ratio returned to Vehicle control levels which was not the case in EDS + S

188 TAC and maintained miR-133a expression near vehicle control levels, which coincided with (1) a decre

189 he multiple tyrosine inhibitor nintedanib or vehicle (controls); liver tissues were collected and his

190 d the median survival to 163 d compared with vehicle controls (log-rank test, p = 0.0001), in contras

191 Rats received vehicle (controls), lovastatin (30 mg/kg), or atorvastat

192 Animals were randomized to vehicle control, low-dose A2AR agonist, or high-dose A2A

193 Vehicle control metrics, such as lateral acceleration va

194 icient mice administered P(4) was similar to vehicle control mice and significantly reduced compared

195 cient mice administered P(4) were similar to vehicle control mice and the latency to immobility was s

196 All vehicle control mice established HCV infection, reaching

197 d a similar number of central entries as did vehicle control mice, both were lower than central entri

198 Compared to mice on WDSW and vehicle controls, mice receiving WDSW + saroglitazar had

199 ar old) cynomolgus monkeys were given either vehicle control (n = 1) or TAM (n = 3) twice daily for a

200 ed with the complement inhibitor CR2-Crry or vehicle control (n=6).

201 Although no changes were observed in the vehicle controls (n = 5), chronic infusions of 7.5 micro

202 = 8), 7.8 x 10(9) PEVs (PEV group, n = 8) or Vehicle (Control, n = 16) following severe trauma.

203 2 mug (g body weight)(-1) day(-1), n = 7) or vehicle (control, n = 9) were infused in pregnant C57/BL

204 were treated with CP-690,550 (n = 18) or its vehicle (controls, n = 3) and were euthanized at day 90

205 pharmacologically lesion the 5-HT system, or vehicle (control; n = 14).

206 tumor volumes were injected s.c. daily with vehicle (control; n = 6), fulvestrant (1 mg/d; n = 7), l

207 Treatment groups received isotonic saline vehicle (control; n = 6), lipopolysaccharide (3.0 mg/kg,

208 Following isotonic saline vehicle (control; n = 6), lipopolysaccharide (3.0 mg/kg,

209 hMSCs) (n = 7) or cell-free carrier vehicle (vehicle control; n = 7).

210 ats were divided into four treatment groups: vehicle-control, noise-only, CAE-only and CAE+noise.

211 1 hour before induction of inflammation), or vehicle control on acute inflammation in an air-pouch mo

212 1 mice were treated with BPA (5 mg/kg IP) or vehicle control on d 9-16 of pregnancy.

213 Vehicle control or AAV viruses (1 x 10(12 )GC/mouse in 2

214 a daily intraperitoneal injection (i.p.) of vehicle control or Delta9-THC (3 mg/kg) from embryonic (

215 ypothesis, adult female mice were dosed with vehicle control or DiNP doses ranging from 0.02 to 200 m

216 Pregnant mice were orally administered vehicle control or DOSS at times and doses comparable to

217 an initial stabilisation period followed by vehicle control or drug administration.

218 sions were extremely rare in mice exposed to vehicle control or filtered air.

219 sence or absence of estrogen and for ethanol vehicle control or fulvestrant treatment, a selective ER

220 Cultures of TM cells were treated with vehicle control or latanoprost acid for 24 hours.

221 CBSM cell cultures were treated with vehicle control or latanoprost acid for 24 hours.

222 iven MI and animals were treated either with vehicle control or p1158/59 matricryptin.

223 were cultured for 7 days, after which either vehicle control or SSRI (10(-6) mol/L) was added for 2 h

224 ltured in the presence of interleukin-2 with vehicle control or the SSRI (10(-6) mol/L) for 2 hours.

225 high-fat diet were orally administered with vehicle control or UFP (40 mug/mouse/day) for 3 days a w

226 eceived intra-articular injections of Ringer vehicle (control) or an activator of classical PKC isofo

227 ley rats 3 weeks after treatment with either vehicle (control) or streptozotocin (diabetic).

228 and treated with dimethyl sulfoxide (DMSO) (vehicle control) or with the PI3K inhibitor LY294002 or

229 erwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg

230 road salt (200 or 1000 mg Cl(-)/L), ethanol-vehicle control, or no-stressor control) and subsequentl

231 To test the hypothesis, vehicle control- or TCDD-treated mice were intranasally

232 ith 100 mug/kg beta-estradiol 17-valerate or vehicle (control) over 7 and 28 days.

233 a K1-negative strain or to treatment with a vehicle control (P < 0.0001).

234 omycin alone, and 58% (95% CI, 50 to 67) for vehicle control (P<0.001 for each treatment group vs. th

235 s post TAC, respectively, when compared with vehicle control (P<0.05).

236 s (G(0) phase) from 24% to 48% compared with vehicle control (P<0.05).

237 mean 92.2% (range, 86.0%-99.4%) reduction vs vehicle controls (P < .0001) and in prolonged animal sur

238 by 34% (iv) and 14% (IP) in comparison with vehicle controls (p < .05 for iv treatment).

239 (CAPZB, CAPZA2, ADD1, and ADK) compared with vehicle controls (P < .05).

240 rk (37 +/- 8.3%) of treated eyes relative to vehicle controls (p < 0.005; 5 muM Lat-B).

241 etinal fluid reabsorption when compared with vehicle controls (P < 0.05; repeated measures ANOVA).

242 macrophages/activated microglia compared to vehicle controls (p<0.025); however, these changes in th

243 Compared with vehicle controls, paricalcitol significantly attenuated

244 Compared with vehicle controls, PF-04178903-treated mice demonstrated

245 mice with orthotopic cecal tumors were given vehicle (controls), PGE2, celecoxib, and/or Ono-AE3-208.

246 ive, randomized, multicenter, double-masked, vehicle-controlled phase 3 studies.

247 We conducted a randomized, vehicle-controlled phase 3 trial of topical treatments c

248 Compared with vehicle controls, PHY administration significantly incre

249 CAI (100 mg/kg) or vehicle control polyethylene glycol-400 (PEG-400) was gi

250 xenografted with ATLL cells and treated with vehicle control, PS-341, Zol, or a combination of PS-341

251 rom all three treatment groups and also from vehicle control rats on day six, following five consecut

252 molality by approximately 2-fold compared to vehicle control rats, even under conditions of maximum a

253 earning (inhibitory avoidance) compared with vehicle control rats.

254 Unlike (vehicle) control rats, SH induced a significant pLTF in

255 tion, whereas 100% of the mice receiving the vehicle control remained normoglycemic.

256 The vehicle control requirements are quantified with respect

257 ncreased in (+)-JQ1 treated mice compared to vehicle control, similar to the original study.

258 as a 1 mm bolus, into the perfusate: saline vehicle (control); sodium hydrogen sulphide (NaHS); NaHS

259 ontrols; hydrochloric acid aspiration alone; vehicle control solution followed 24 hrs later by mechan

260 pproved drug FTY720 (fingolimod, Gilenya) or vehicle control solution from 5 months of age.

261 of the vav promoter were administered G6 or vehicle control solution, and efficacy was determined by

262 5 (64.1%) and 15 (36.6%), respectively, were vehicle-controlled studies.

263 Microinjections into the PnO of saline (vehicle control), the GABA(A) receptor agonist muscimol,

264 e for 24 hours following pretreatment with a vehicle control, the cysteine biosynthesis inhibitor pro

265 Compared to vehicle controls there was a significant reduction in sp

266 from 0.02 to 1.4 endotoxin units (EUs) or a vehicle control to both eyes.

267 untreated control group in addition to DMSO vehicle control to check for solvent toxicity.

268 ce after 9 Gy TBI 12.5-25% compared with the vehicle control treated group, respectively.

269 creased in the TCDD-treated mice relative to vehicle control-treated mice.

270 nal cell carcinoma cells did not differ from vehicle control treatment, similar to the original study

271 n and FLT3 inhibition than to single-drug or vehicle control treatment, whereas AML cells with wild-t

272 l as long-term spatial memory, compared with vehicle control treatment.

273 Compared with the saline (vehicle) control treatment, prenatal dexamethasone signi

274 scular endothelial growth factor receptor or vehicle-control treatment (10 per group) in HaCaT-ras A-

275 We demonstrated that, in comparison to vehicle-control treatment, one of the brain-targeted pol

276 cetin-3-O-glucuronide treatment, compared to vehicle-control treatment, significantly improved AD-typ

277 compared with a 1 g/kg dose, and 0.15 M NaCl vehicle control treatments.

278 We conducted a randomized, double-blind, vehicle-controlled trial to assess the efficacy of resiq

279 S) is a phase 3, multicenter, double-masked, vehicle-controlled trial.

280 dlPFC-dependent task performance relative to vehicle control values (group young OVX+Veh) but nonethe

281 ng performance over a 30-min delay to 27% of vehicle controls values.

282 clate in bioabsorbable vehicle (DHV) or with vehicle control (VC) in vivo.

283 phonate (zoledronate [Zol]), PTH, or saline (vehicle control [VC]) was administered for 10 days (n =

284 A tube of topical ivermectin or vehicle control was dispensed on day 1, to be applied to

285 A DMSO or PBS vehicle control was included for each experiment based o

286 Poor vehicle control was independently associated with greate

287 ALN, parathyroid hormone (PTH), or saline (vehicle control) was administered.

288 lasty with local delivery of RvD2 (10 nM vs. vehicle control) was employed to examine effects on vasc

289 d to 1 mM PTU (EC(50)=0.88 mM), 1 mM MMI, or vehicle control (water) from stages 2 to 45.

290 e administration of either corticosterone or vehicle control, we tested the birds' responses to the c

291 receiving ivermectin than patients receiving vehicle control were louse-free on day 2 (94.9% vs. 31.3

292 ne (MCF-7) treated with 17-beta-estradiol or vehicle control were used to develop a mass-action kinet

293 8 nanocrystals (30 and 60 mg/kg body wt) and vehicle controls were injected i.p. immediately after I/

294 the 5-HT4R antagonist GR113808 (1 mg/kg), or vehicle (control) were delivered by enema to wild-type o

295 ter in the PQQ-treated group compared to the vehicle controls when PQQ was given at 10 and 3 mg/kg, b

296 tly reduced conditioned defeat compared with vehicle controls, whereas the CRF-sub-1 receptor antagon

297 eated CD18-deficient PL/J mice compared with vehicle controls, which was associated with decreased CD

298 alled WR 279,396), 15% paromomycin alone, or vehicle control (with the same base as the other two cre

299 uced plasma TG levels by 51% compared to the vehicle control without affecting plasma cholesterol lev

300 f the atrial refractory period compared with vehicle controls without affecting the ventricular refra